KR102055172B1 - 마이크로rna 화합물 및 mir-21 활성 조절 방법 - Google Patents

마이크로rna 화합물 및 mir-21 활성 조절 방법 Download PDF

Info

Publication number
KR102055172B1
KR102055172B1 KR1020137031227A KR20137031227A KR102055172B1 KR 102055172 B1 KR102055172 B1 KR 102055172B1 KR 1020137031227 A KR1020137031227 A KR 1020137031227A KR 20137031227 A KR20137031227 A KR 20137031227A KR 102055172 B1 KR102055172 B1 KR 102055172B1
Authority
KR
South Korea
Prior art keywords
certain embodiments
nucleoside
nucleosides
mir
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137031227A
Other languages
English (en)
Korean (ko)
Other versions
KR20140033062A (ko
Inventor
발크리셴 바트
Original Assignee
레굴루스 테라퓨틱스 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레굴루스 테라퓨틱스 인크 filed Critical 레굴루스 테라퓨틱스 인크
Publication of KR20140033062A publication Critical patent/KR20140033062A/ko
Application granted granted Critical
Publication of KR102055172B1 publication Critical patent/KR102055172B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
KR1020137031227A 2011-04-25 2012-04-25 마이크로rna 화합물 및 mir-21 활성 조절 방법 Active KR102055172B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161478767P 2011-04-25 2011-04-25
US61/478,767 2011-04-25
US201161565779P 2011-12-01 2011-12-01
US61/565,779 2011-12-01
PCT/US2012/034880 WO2012148952A1 (en) 2011-04-25 2012-04-25 Microrna compounds and methods for modulating mir-21 activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197015054A Division KR20190063482A (ko) 2011-04-25 2012-04-25 마이크로rna 화합물 및 mir-21 활성 조절 방법

Publications (2)

Publication Number Publication Date
KR20140033062A KR20140033062A (ko) 2014-03-17
KR102055172B1 true KR102055172B1 (ko) 2020-01-23

Family

ID=46025979

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137031227A Active KR102055172B1 (ko) 2011-04-25 2012-04-25 마이크로rna 화합물 및 mir-21 활성 조절 방법
KR1020197015054A Ceased KR20190063482A (ko) 2011-04-25 2012-04-25 마이크로rna 화합물 및 mir-21 활성 조절 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197015054A Ceased KR20190063482A (ko) 2011-04-25 2012-04-25 마이크로rna 화합물 및 mir-21 활성 조절 방법

Country Status (30)

Country Link
US (7) US20120270928A1 (enExample)
EP (3) EP3211082B1 (enExample)
JP (2) JP6320292B2 (enExample)
KR (2) KR102055172B1 (enExample)
CN (3) CN103620035B (enExample)
AU (4) AU2012249851B2 (enExample)
BR (1) BR112013027187A2 (enExample)
CA (2) CA2833615C (enExample)
CL (1) CL2013003105A1 (enExample)
CO (1) CO6821889A2 (enExample)
CY (1) CY1120304T1 (enExample)
DK (2) DK2702155T3 (enExample)
EA (1) EA025894B1 (enExample)
ES (2) ES2868950T3 (enExample)
HR (2) HRP20170557T2 (enExample)
HU (2) HUE054129T2 (enExample)
IL (3) IL229032B (enExample)
LT (2) LT3211082T (enExample)
MX (5) MX2013012452A (enExample)
MY (2) MY175336A (enExample)
NZ (1) NZ717921A (enExample)
PH (1) PH12013502199A1 (enExample)
PL (2) PL2702155T3 (enExample)
PT (2) PT3211082T (enExample)
RS (1) RS61775B1 (enExample)
SG (1) SG194636A1 (enExample)
SI (2) SI3211082T1 (enExample)
TW (2) TWI607016B (enExample)
UA (1) UA115652C2 (enExample)
WO (1) WO2012148952A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2534302T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
CN103620035B (zh) 2011-04-25 2021-04-23 赛诺菲 用于调节mir-21活性的微rna化合物以及方法
WO2013153082A1 (en) * 2012-04-10 2013-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of nonalcoholic steatohepatitis
BR112014026639A8 (pt) * 2012-04-25 2018-01-16 Regulus Therapeutics Inc compostos , métodos de inibição da atividade de mir-21 , método para diminuir a expressão de colágeno , método para tratar , prevenir ou atrasar o início de uma doença , método de tratamento de um distúrbio fibroproliferativo e usos de um composto.
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
RU2015119411A (ru) 2012-11-15 2017-01-10 Рош Инновейшен Сентер Копенгаген А/С Конъюгаты антисмысловых соединений, направленные на аполипопротеин в
NZ630890A (en) 2013-05-01 2017-09-29 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122
EP3060664B1 (en) * 2013-10-25 2021-07-07 Sanofi Microrna compounds and methods for modulating mir-21 activity
KR101625755B1 (ko) 2013-11-18 2016-05-30 울산대학교 산학협력단 ｍｉＲＮＡ 스폰지 및 이의 용도
WO2015113922A1 (en) * 2014-01-30 2015-08-06 Roche Innovation Center Copenhagen A/S Poly oligomer compound with biocleavable conjugates
CN105734127A (zh) * 2016-02-29 2016-07-06 上海中医药大学 miR-21-3p在制备用于检测早期急性肾损伤的试剂中的用途
EP3449001B1 (en) 2016-04-29 2021-12-08 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
CN110177544A (zh) 2016-11-29 2019-08-27 普尔泰克健康有限公司 用于递送治疗剂的外泌体
ES2994431T3 (en) 2017-09-22 2025-01-23 Univ Washington In situ combinatorial labeling of cellular molecules
CN108148911B (zh) * 2018-03-02 2019-11-05 广州医科大学附属第二医院 miR-582在制备前列腺癌骨转移的诊断、预后试剂盒及药物中的应用
WO2019217369A1 (en) 2018-05-08 2019-11-14 Regulus Therapeutics Inc. Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect
CN110747266A (zh) * 2018-07-23 2020-02-04 深圳先进技术研究院 miR-21和miR-21拮抗剂在抑制预防/治疗1型糖尿病中的应用
CN109880907A (zh) * 2019-03-26 2019-06-14 中国人民解放军第八一医院 一种肝癌细胞侵袭转移的分子机制研究方法
US11965162B2 (en) 2020-04-16 2024-04-23 The Johns Hopkins University MicroRNA and inhibitors thereof and methods of treatment
WO2022165092A1 (en) * 2021-01-29 2022-08-04 Angion Biomedica Corp. Methods for treatment of fibrotic diseases
WO2025110217A1 (ja) * 2023-11-22 2025-05-30 国立大学法人東海国立大学機構 嚢胞性腎疾患の予防及び／又は治療剤
CN120505413A (zh) * 2025-07-15 2025-08-19 湖南工程学院 一种基于引物交换反应和G-四链体检测AKI相关miRNA的探针体系及方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007027894A2 (en) * 2005-08-29 2007-03-08 Isis Pharmaceuticals, Inc. Antisense compounds having enhanced anti-microrna activity
WO2009043353A2 (en) * 2007-10-04 2009-04-09 Santaris Pharma A/S Micromirs
WO2009106367A1 (en) 2008-02-27 2009-09-03 Julius Maximilians-Universität Würzburg Microrna (mirna) and downstream targets for diagnostic and therapeutic purposes
WO2010099161A1 (en) 2009-02-26 2010-09-02 The Ohio State University Research Foundation Micrornas in never-smokers and related materials and methods

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1187084C (zh) 1998-05-22 2005-02-02 博伊斯镇国家研究医院 α1β1整合蛋白受体抑制剂和TGF－β1抑制剂制备用于治疗肾病的药物组合物的用途
US20060008817A1 (en) * 2000-12-08 2006-01-12 Invitrogen Corporation Methods and compositions for generating recombinant nucleic acid molecules
WO2003029459A2 (en) 2001-09-28 2003-04-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Micro-rna molecules
AU2003291753B2 (en) 2002-11-05 2010-07-08 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
EP1648914A4 (en) 2003-07-31 2009-12-16 Regulus Therapeutics Inc OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
ATE555118T1 (de) 2003-08-28 2012-05-15 Takeshi Imanishi Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung
JP5192234B2 (ja) 2004-08-10 2013-05-08 アルナイラム ファーマシューティカルズ， インコーポレイテッド 化学修飾オリゴヌクレオチド
EP1802331A2 (en) 2004-09-08 2007-07-04 Boys Town National Research Hospital Treatment of glomerular basement membrane disease involving matrix metalloproteinase-12
ES2534302T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
EP1838870A2 (en) 2004-12-29 2007-10-03 Exiqon A/S NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs
US6995235B1 (en) 2005-05-02 2006-02-07 Univation Technologies, Llc Methods of producing polyolefins and films therefrom
JP5342881B2 (ja) 2006-01-27 2013-11-13 アイシス ファーマシューティカルズ， インコーポレーテッド ６−修飾された二環式核酸類似体
AU2007211082B2 (en) 2006-01-27 2012-09-27 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of microRNAs
CA3024953A1 (en) 2006-04-03 2007-10-11 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
PL2666859T3 (pl) * 2006-04-03 2019-09-30 Roche Innovation Center Copenhagen A/S Kompozycja farmaceutyczna zawierająca antysensowne oligonukleotydy anty-miRNA
MX2009003548A (es) 2006-10-03 2009-04-15 Alnylam Pharmaceuticals Inc Formulaciones que contienen lipidos.
EP2476762B1 (de) 2006-10-09 2014-01-08 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) zur Diagnose und Therapie von Herzerkrankungen
AU2007333107A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. miR-21 regulated genes and pathways as targets for therapeutic intervention
US8048998B2 (en) 2007-01-19 2011-11-01 Exiqon A/S Mediated cellular delivery of LNA oligonucleotides
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
WO2008151631A2 (en) 2007-06-15 2008-12-18 Exiqon A/S Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
CA2692579C (en) 2007-07-05 2016-05-03 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
WO2009058907A2 (en) * 2007-10-29 2009-05-07 Isis Pharmaceuticals, Inc. Targeting micrornas for the treatment of liver cancer
WO2009091972A2 (en) 2008-01-18 2009-07-23 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
WO2009099326A1 (en) 2008-02-08 2009-08-13 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
WO2009109665A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
CN102803284B (zh) 2009-06-08 2015-11-25 米拉根医疗公司 用于miRNA抑制剂和模拟物的化学修饰基序
WO2011126842A2 (en) 2010-03-30 2011-10-13 Regulus Therapeutics Inc. Targeting micrornas for the treatment of cardiac disorders
CN103620035B (zh) 2011-04-25 2021-04-23 赛诺菲 用于调节mir-21活性的微rna化合物以及方法
WO2013013165A2 (en) 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
BR112014026639A8 (pt) 2012-04-25 2018-01-16 Regulus Therapeutics Inc compostos , métodos de inibição da atividade de mir-21 , método para diminuir a expressão de colágeno , método para tratar , prevenir ou atrasar o início de uma doença , método de tratamento de um distúrbio fibroproliferativo e usos de um composto.
CA2876180C (en) 2012-06-21 2019-11-19 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
JP6352269B2 (ja) 2012-09-26 2018-07-04 ミルクス セラピューティクス アクティーゼルスカブＭｉｒｒｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａ／Ｓ オフターゲットプロファイルの改善されたオリゴマー
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007027894A2 (en) * 2005-08-29 2007-03-08 Isis Pharmaceuticals, Inc. Antisense compounds having enhanced anti-microrna activity
WO2009043353A2 (en) * 2007-10-04 2009-04-09 Santaris Pharma A/S Micromirs
WO2009106367A1 (en) 2008-02-27 2009-09-03 Julius Maximilians-Universität Würzburg Microrna (mirna) and downstream targets for diagnostic and therapeutic purposes
WO2010099161A1 (en) 2009-02-26 2010-09-02 The Ohio State University Research Foundation Micrornas in never-smokers and related materials and methods

Also Published As

Publication number Publication date
US12331294B2 (en) 2025-06-17
CA2833615A1 (en) 2012-11-01
US20180155719A1 (en) 2018-06-07
KR20190063482A (ko) 2019-06-07
SI3211082T1 (sl) 2021-08-31
EP2702155B1 (en) 2017-02-01
PT3211082T (pt) 2021-04-28
CN103620035B (zh) 2021-04-23
AU2017219156B2 (en) 2020-01-02
HUE031595T2 (en) 2017-07-28
PL2702155T3 (pl) 2017-09-29
IL229032A0 (en) 2013-12-31
TW201300404A (zh) 2013-01-01
JP2014518619A (ja) 2014-08-07
AU2012249851B2 (en) 2017-06-08
CA3165397A1 (en) 2012-11-01
RS61775B1 (sr) 2021-05-31
HRP20170557T1 (hr) 2017-06-16
DK3211082T3 (da) 2021-05-10
MX2013012452A (es) 2014-11-21
AU2020201403A1 (en) 2020-03-12
HRP20210616T1 (hr) 2021-05-28
CN113249381A (zh) 2021-08-13
US20160138016A1 (en) 2016-05-19
IL266529A (en) 2019-07-31
EP3211082B1 (en) 2021-02-17
EP3211082A1 (en) 2017-08-30
MY187685A (en) 2021-10-11
AU2017219156A1 (en) 2017-09-21
MX2019003089A (es) 2019-07-18
ES2621863T3 (es) 2017-07-05
US9181547B2 (en) 2015-11-10
CY1120304T1 (el) 2019-07-10
WO2012148952A1 (en) 2012-11-01
CL2013003105A1 (es) 2014-08-01
NZ616748A (en) 2016-03-31
KR20140033062A (ko) 2014-03-17
EA201391492A1 (ru) 2014-04-30
US8912161B2 (en) 2014-12-16
AU2022203067A1 (en) 2022-05-26
TW201811812A (zh) 2018-04-01
US20120270928A1 (en) 2012-10-25
HRP20170557T2 (hr) 2020-02-21
JP6320292B2 (ja) 2018-05-09
EP3933040A1 (en) 2022-01-05
AU2012249851A8 (en) 2013-11-14
CO6821889A2 (es) 2013-12-31
AU2012249851A1 (en) 2013-10-31
UA115652C2 (uk) 2017-12-11
HUE054129T2 (hu) 2021-08-30
ES2621863T9 (es) 2020-02-13
MX2022006595A (es) 2022-07-01
JP2018121646A (ja) 2018-08-09
NZ717921A (en) 2017-09-29
CA2833615C (en) 2022-08-30
IL229032B (en) 2021-01-31
MY175336A (en) 2020-06-19
TWI607016B (zh) 2017-12-01
DK2702155T3 (en) 2017-05-01
CN103620035A (zh) 2014-03-05
EP2702155B9 (en) 2020-01-01
BR112013027187A2 (pt) 2017-06-06
LT3211082T (lt) 2021-05-10
MX393138B (es) 2025-03-24
CN113151272A (zh) 2021-07-23
PT2702155T (pt) 2017-04-03
PL3211082T3 (pl) 2021-08-02
MX2022000212A (es) 2022-04-01
IL273381A (en) 2020-05-31
MX2019003090A (es) 2019-07-18
PH12013502199A1 (en) 2014-01-27
EP2702155A1 (en) 2014-03-05
EA025894B1 (ru) 2017-02-28
ES2868950T3 (es) 2021-10-22
US20220098583A1 (en) 2022-03-31
SG194636A1 (en) 2013-12-30
SI2702155T1 (sl) 2017-07-31
US9790496B2 (en) 2017-10-17
LT2702155T (lt) 2017-05-10
US20140329887A1 (en) 2014-11-06
TWI698445B (zh) 2020-07-11
US20140107183A1 (en) 2014-04-17
HK1243130A1 (en) 2018-07-06
US20200291400A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
KR102055172B1 (ko) 마이크로rna 화합물 및 mir-21 활성 조절 방법
KR102369722B1 (ko) 마이크로rna 화합물 및 mir-21 활성 조절 방법
HK40065959A (en) Microrna compounds and methods for modulating mir-21 activity
HK1243130B (en) Microrna compounds and methods for modulating mir-21 activity
HK1207115B (en) Microrna compounds and methods for modulating mir-21 activity
HK1195585A (en) Microrna compounds and methods for modulating mir-21 activity
HK1195585B (en) Microrna compounds and methods for modulating mir-21 activity

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131125

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170404

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180530

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20190226

Patent event code: PE09021S02D

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190524

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190925

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20191206

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20191206

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20221027

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20241029

Start annual number: 6

End annual number: 6